

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

StarDrop

RRID:SCR_014902

Type: Tool

Proper Citation

StarDrop (RRID:SCR_014902)

Resource Information

URL: <http://www.optibrium.com/stardrop/index.php>

Proper Citation: StarDrop (RRID:SCR_014902)

Description: Software toolkit for drug design and discovery, including plugins for in silico compound optimization, compound selection and integration into other databases.

Resource Type: software resource, software application

Keywords: drug discovery, in silico compound optimization, pharmacology, database, integration, FASEB list

Availability: Commercial

Resource Name: StarDrop

Resource ID: SCR_014902

License: Available licenses include site licenses, floating licenses and fixed licenses.

Record Creation Time: 20220129T080323+0000

Record Last Update: 20260801T191106+0000

Ratings and Alerts

No rating or validation information has been found for StarDrop.

No alerts have been found for StarDrop.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 54 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhou B, et al. (2025) Structure-Based Analysis of Semisynthetic Anti-TB Rufomycin Analogues. *Journal of natural products*, 88(4), 907.

Erlitz KS, et al. (2025) Piperazine-based P2X4 receptor antagonists. *Archiv der Pharmazie*, 358(1), e2400860.

Zhang X, et al. (2025) Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy. *BMC biology*, 23(1), 27.

Hathi P, et al. (2025) Extracellular adenosine deamination primes tip organizer development in *Dictyostelium*. *eLife*, 14.

Attwa MW, et al. (2024) Characterization of the in vitro metabolic profile of nazartinib in HLMS using UPLC-MS/MS method: In silico metabolic lability and DEREK structural alerts screening using StarDrop software. *Heliyon*, 10(13), e34109.

Watson SJ, et al. (2024) The Tuberculosis Drug Candidate SQ109 and Its Analogs Have Multistage Activity against *Plasmodium falciparum*. *ACS infectious diseases*, 10(9), 3358.

Pai R, et al. (2024) Computational investigation of naturally occurring anticancer agents in regulating Hedgehog pathway proteins. *PloS one*, 19(12), e0311307.

Wu K, et al. (2024) TamGen: drug design with target-aware molecule generation through a chemical language model. *Nature communications*, 15(1), 9360.

Attwa MW, et al. (2024) Assessment of the in vitro metabolic stability of CEP-37440, a selective FAK/ALK inhibitor, in HLMS using fast UPLC-MS/MS method: in silico metabolic lability and DEREK alerts screening. *Frontiers in chemistry*, 12, 1323738.

Alsibae AM, et al. (2024) Ion Trap LC/MS reveals the generation of reactive intermediates in acalabrutinib metabolism: phase I metabolic profiling and bioactivation pathways elucidation. *RSC advances*, 14(23), 16170.

Bai YB, et al. (2023) Virtual Screening and In Vitro Experimental Verification of LuxS Inhibitors for *Escherichia coli* O157:H7. *Microbiology spectrum*, 11(2), e0350222.

Attwa MW, et al. (2023) Rapid LC-MS/MS Bosutinib Quantification with Applications in Metabolic Stability Estimation. *Molecules (Basel, Switzerland)*, 28(4).

Attwa MW, et al. (2023) Assessment of In Silico and In Vitro Selpercatinib Metabolic Stability in Human Liver Microsomes Using a Validated LC-MS/MS Method. *Molecules (Basel, Switzerland)*, 28(6).

Alsibae AM, et al. (2023) Investigation of Fenebrutinib Metabolism and Bioactivation Using MS3 Methodology in Ion Trap LC/MS. *Molecules (Basel, Switzerland)*, 28(10).

Liu Y, et al. (2022) Discovery of Chitin Deacetylase Inhibitors through Structure-Based Virtual Screening and Biological Assays. *Journal of microbiology and biotechnology*, 32(4), 504.

Gierse RM, et al. (2022) First crystal structures of 1-deoxy-D-xylulose 5-phosphate synthase (DXPS) from *Mycobacterium tuberculosis* indicate a distinct mechanism of intermediate stabilization. *Scientific reports*, 12(1), 7221.

Flint AL, et al. (2022) Modified Curcumins as Potential Drug Candidates for Breast Cancer: An Overview. *Molecules (Basel, Switzerland)*, 27(24).

Wang X, et al. (2021) A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2. *Environment international*, 147, 106361.

Shi W, et al. (2021) Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer. *Nature communications*, 12(1), 2812.

Attwa MW, et al. (2021) LC-MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation. *Drug design, development and therapy*, 15, 3915.